ICON Early Phase Services

San Antonio, Texas 78232

3 studies enrolling now · 31 studies all time

What they study most

Alzheimer's Disease, COVID-19, Critical Limb Ischemia, Cystic Fibrosis, Cystic Fibrosis - Complete, Drug Interaction, Food-effect, Healthy, Healthy Adult Subjects, Healthy Volunteer, Healthy Volunteer - Complete, Healthy Volunteers

Studies at this site

• A Study of LY4088044 in Healthy Participants — Recruiting now
• A Study of LY4064912 in Healthy Participants and With Overweight or Obesity — Recruiting now
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight — Starting soon
• A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants — Completed
• A Study of LY3971297 in Healthy Participants — Running, not enrolling
• A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants — Completed
• A Study of LY3502970 in Healthy Overweight and Obese Participants — Completed
• Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects — Completed
• A Study of Imlunestrant (LY3484356) in Female Healthy Participants — Completed
• A Study of RGLS8429 in Healthy Volunteers — Completed
• A Study of LY3541105 in Healthy and Overweight Participants — Completed
• Food-effect Study of Ecopipam Pharmacokinetics — Completed
• A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices — Completed
• Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects — Completed
• A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese — Completed
• A Relative Bioavailability Study of LY3454738 in Healthy Participants — Completed
• Continuous Intraosseous Vascular Access Over 48 Hours — Completed
• A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices — Completed
• FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms — Completed
• A Study of LY3305677 in Participants With Obesity Or Overweight — Completed
• A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects — Stopped early
• Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport — Completed
• Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants — Completed
• A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease — Completed
• Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites — Completed
• A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole — Completed
• Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis — Completed
• A Safety and Tolerability Study of RJX Drug Product in Healthy Participants — Completed
• Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis — Completed
• Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate — Completed
• Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers — Completed